NASDAQ$AURA
Aura Biosciences Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Aura Biosciences reported Q3 2025, a net loss of $26.1M.
For Q3 2025, Aura Biosciences reported a net loss of $26.1M. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.
- Net loss $26.1M.
- Aura Biosciences updated strategic and capital priorities in the filing.
- Aura Biosciences updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$600K
Forward guidance
The filing discusses Aura Biosciences's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Aura Biosciences cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
- Pipeline milestones remain the primary value driver.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
- Clinical-stage spend continues ahead of commercial revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q3 2025
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro